Clarity Pharmaceuticals Ltd. (AU:CU6) has released an update.
Clarity Pharmaceuticals Ltd has reported changes in the interests of director Robert Bain Thomas, involving both direct and indirect holdings in the company’s securities. The adjustments, effective as of April 29, 2024, include the acquisition of additional shares across four different entities, with a total non-cash consideration valued at approximately $87,000. These entities include personal holdings, a pension fund, a private company, and a charitable foundation where Mr. Thomas holds various positions of influence.
For further insights into AU:CU6 stock, check out TipRanks’ Stock Analysis page.
